This week in techniques



Licensing status

Publication and contact information

Drug platforms

IL-15 and soluble IL-15 receptor a-chain
(sIL-15RA) heterodimers

Mouse studies suggest heterodimers of IL-15 and sIL-15RA could be more potent than IL-15 monomers for stimulating the immune system against diseases such as cancer. Cell lines that produce IL-15 and sIL-15RA were used to generate stable heterodimers of the molecules. In mice, the heterodimers showed longer half-life, higher plasma stability and more potent stimulation of lymphocyte proliferation than did IL-15 monomers. Next steps include scaling up the process to generate GMP material as well as a planned Phase I trial in cancer.

SciBX 6(21); doi:10.1038/scibx.2013.533
Published online May 30, 2013

Patent application filed; licensed to Marine Polymer Technologies Inc.

Chertova, E. et al. J. Biol. Chem.; published online May 6, 2013;
Contact: George N. Pavlakis, National Cancer Institute, Bethesda, Md.